{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:37:38Z","timestamp":1778582258069,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10637-019-00749-9","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T03:54:41Z","timestamp":1551844481000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A phase I study to determine the maximum tolerated dose of trifluridine\/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-2893","authenticated-orcid":false,"given":"Mitsukuni","family":"Suenaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Seimiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/cncr.22125","volume":"107","author":"DS Hong","year":"2006","unstructured":"Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107:1383\u20131390","journal-title":"Cancer"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"749_CR3","unstructured":"NCCN. Clinical practice guideline: Colon cancer. Ver. 4. 2018. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 27 Dec 2018"},{"key":"749_CR4","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386\u20131422","journal-title":"Ann Oncol"},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44\u201370","journal-title":"Ann Oncol"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1200\/JCO.2006.10.4380","volume":"25","author":"A de Gramont","year":"2007","unstructured":"de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andr\u00e9 T, Tabah-Fisch I, Tournigand C (2007) Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 25:3224\u20133229","journal-title":"J Clin Oncol"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"M Suenaga","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 9:3099\u20133108","journal-title":"Drug Des Devel Ther"},{"key":"749_CR9","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545\u2013549","journal-title":"Int J Mol Med"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.bjc.6603549","volume":"96","author":"OH Temmink","year":"2007","unstructured":"Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ (2007) Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 96:231\u2013240","journal-title":"Br J Cancer"},{"issue":"suppl_8","key":"749_CR11","doi-asserted-by":"publisher","first-page":"viii150","DOI":"10.1093\/annonc\/mdy281","volume":"29","author":"A Calvo Ferrandiz","year":"2018","unstructured":"Calvo Ferrandiz A, Dahan L, Hollebecque A, Prager G, Andre T, Argiles Martinez G et al (2018) Safety run-in evaluation of the phase I trial of trifluridine\/tipiracil (FTD\/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients with metastatic colorectal cancer. Ann Oncol 29(suppl_8):viii150\u2013viii204. https:\/\/doi.org\/10.1093\/annonc\/mdy281","journal-title":"Ann Oncol"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3892\/etm.2011.244","volume":"2","author":"N Suzuki","year":"2011","unstructured":"Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M (2011) Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med 2:393\u2013397","journal-title":"Exp Ther Med"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/annonc\/mdx035","volume":"28","author":"M Suenaga","year":"2017","unstructured":"Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ (2017) Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol 28:1015\u20131022","journal-title":"Ann Oncol"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm2351","volume":"9","author":"D Branzei","year":"2008","unstructured":"Branzei D, Foiani M (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9:297\u2013308","journal-title":"Nat Rev Mol Cell Biol"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0006-2952(03)00260-0","volume":"66","author":"S Faivre","year":"2003","unstructured":"Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225\u2013237","journal-title":"Biochem Pharmacol"},{"key":"749_CR16","first-page":"4605","volume":"35","author":"M Nukatsuka","year":"2015","unstructured":"Nukatsuka M, Nakagawa F, Takechi T (2015) Efficacy of combination chemotherapy using a novel Oral chemotherapeutic agent, TAS-102, with Oxaliplatin on human colorectal and gastric Cancer xenografts. Anticancer Res 35:4605\u20134615","journal-title":"Anticancer Res"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bjc.2012.274","volume":"107","author":"T Doi","year":"2012","unstructured":"Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumors. Br J Cancer 107:429\u2013434","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00749-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00749-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00749-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:23Z","timestamp":1678560023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00749-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00749-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest regarding the content discussed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the relevant Institutional Review Boards, the 1964 Helsinki declaration and its later amendments, and our institution\u2019s ethical guidelines for clinical studies. The institutional review board at the Cancer Institute Hospital of the Japanese Foundation of Cancer Research approved the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}